Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLA+BR as Salvage Therapy Prior to ASCT in Relapsed/Refractory DLBCL
NCT04535102Phase 2Withdrawn
- Sponsor
- University of Colorado Denver
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Colorado Denver. Planned start Jan 2021; status: withdrawn.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04535102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04535102.